Aclaris Therapeutics (ACRS) Current Assets (2014 - 2026)

Aclaris Therapeutics' Current Assets history runs 13 years deep, the most recent figure standing at $110.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 1.32% year-over-year to $110.2 million in Q1 2026; TTM through Mar 2026 was $110.2 million, a 1.32% increase from a year earlier, with the FY2025 full-year figure at $96.3 million, down 23.53% from the prior year.
• Current Assets advanced to $110.2 million in Q1 2026 per ACRS's latest filing, from $96.3 million in the prior quarter.
• Across five years, Current Assets topped out at $259.4 million in Q2 2022 and bottomed at $96.3 million in Q4 2025.
• The 5-year median for Current Assets is $128.9 million (2023), against an average of $149.4 million.
• Across the five-year window, Current Assets jumped 41.92% in 2022 and slumped 52.03% in 2023, its largest moves.
• Year by year, Current Assets stood at $231.6 million in 2022, then slumped by 44.35% to $128.9 million in 2023, then slipped by 2.25% to $126.0 million in 2024, then declined by 23.53% to $96.3 million in 2025, then increased by 14.45% to $110.2 million in 2026.
• Per Business Quant, the three latest ACRS Current Assets figures stand at $110.2 million (Q1 2026), $96.3 million (Q4 2025), and $100.6 million (Q3 2025).